5/3/2023-Unusual Options Activity In TTD
$TTD – Bearish flow noted in Trade Desk (62.78 +0.20) with 11,841 puts trading, or 1.7x expected. The Put/Call Ratio is 1.77, while ATM IV is up nearly 2 points on the day. Earnings are expected on 05/10
Similar Posts
6/6/2023-Unusual Options Activity In S
SentinelOne, Inc. is an American cybersecurity company listed on NYSE based in Mountain View, California. The company was founded in 2013 by Tomer Weingarten, Almog Cohen and Ehud Shamir. Weingarten acts as the company’s CEO. Vats Srivatsan is the company’s COO.
2/6/2023-Unusual Options Activity In PINS
Pinterest, Inc. operates as a visual discovery engine in the United States and internationally. The company’s engine allows people to find ideas, such as recipes, home and style inspiration, and others; provides video, product, and idea pins; and offers organizing and planning tools. It shows organic recommendations and advertising engine based on pinners tastes and preferences; and enables pinners with shoppable product pins, which include price, color, and size that redirect to retailer websites.
10/2/2024-Unusual Options Activity In Enovix Corporation (ENVX)
Enovix Corporation is a company that designs, develops, and manufactures lithium-ion batteries for consumer and industrial equipment.
2/9/2024-Unusual Options Activity In OKTA
Okta, Inc. is an American identity and access management company based in San Francisco. It provides cloud software that helps companies manage and secure user authentication into applications, and for developers to build identity controls into applications, website web services and devices.
8/14/2024-Unusual Options Activity In SERV
Serve Robotics develops advanced, AI-powered, low-emissions sidewalk delivery robots that endeavor to make delivery sustainable and economical.
9/20/2023-Unusual Options Activity In VKTX
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company’s lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.
